Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States.
FAIL · Does not pass the screen
23.17 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price23.17 USD at the 5 Nov 2026 close
Our value readOvervalued vs our fair value, as of 5 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 5.48, read 2026-11-01
Ethical does not pass the values gate
Price23.17 USD
Fair value12.79
Ethical score70.0/100
Value readOvervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-11-02Read Markup23.21-0.2% to today Accumulation gives way to Markup after a 51% rise in 5 days
2026-10-28Read Accumulation15.40+50.5% to today ✓Markup gives way to Accumulation with deal news in the headlines
2026-10-21Read Markup14.83+56.2% to today ✓Distribution gives way to Markup after a 12% rise in 3 weeks
2026-10-02Read Distribution13.25+74.9% to today Markdown gives way to Distribution with volume flow in agreement
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Surgery Partners, Inc. holds its Markup at $23.17. Consolidating, no directional conviction, held for 4 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 4 days
Price at the screen
$23.17
Valuation
N/A trailing · 110.21 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.88
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
49.57%
Below 33%
Interest-bearing debt is 49.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
10.37%
Below 49%
Money owed to the company is 10.4% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Surgery Partners,'s business is in a permissible area, but its interest-bearing debt is about 50% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SGRY's ethical verdict changes
Today SGRY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 5 Nov 2026: it trades above our $12.79 fair value estimate, 2.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 81.2% above the base estimate.
Where our models see it going: fair-value estimate $12.79, with a range of $12.79 to $14.71, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Surgical centres priced beyond their slim returns
Picture a chain of outpatient clinics stitching together routine procedures that once filled big hospital wards. Surgery Partners runs that network yet shows a 4% revenue rise, a negative 2% profit margin and just 3% return on equity. At 24.4 times forward earnings the shares sit 21% above our fair value, leaving no margin of safety and a clear pass.
Analysts still cluster around a buy rating with an 18 dollar median target, but the thin growth and absent moat outweigh any ethical green light. Low returns on capital in a competitive field rarely compound into lasting value when multiples already price in optimism.
Valuation gaps like this often close the hard way through earnings pressure or slower procedure volumes. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SGRY trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-06Markup$23.17+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 39%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-05Markup$23.16+0.1%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 39%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markup$23.13-0.3%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 39%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$23.21+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 39%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup · changed$23.21+50.7%Entry 10
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 50.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 39%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 39%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $18.
2026-10-21Markup · changed$14.83+6.8%Entry 8
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 39%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $18.
2026-10-14Distribution$13.89+4.8%Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 39%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $18. Since the last review it dropped out of the Titan Ethical 500; its composite score eased.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 39%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $18.
2026-09-12Markdown · changed$13.93-12.9%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 39%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $18.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
